Scientific Newsroom The press releases below are specifically related to scientific and clinical public disclosures made by Esperion. These are being provided for media professionals who write on scientific topics. For the complete list of all Esperion news please see this page. Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity April 7, 2024 Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 March 25, 2024 U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use March 22, 2024 U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet December 13, 2023 Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023 November 13, 2023 Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023 November 11, 2023 American College of Cardiology Program to Increase Cholesterol Screenings September 12, 2023 Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023 August 26, 2023 Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions June 24, 2023 Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023 June 15, 2023 International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk Mar 08, 2023 Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients Mar 04, 2023 CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC) Dec 19, 2022 Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint Dec 07, 2022 Esperion Announces Bempedoic Acid (NEXLETOL®) Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway Aug 06, 2022 Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin Jun 03, 2022 Esperion Announces Five Abstracts Accepted for Presentation at the National Lipid Association Scientific Sessions May 31, 2022 Esperion Announces Publication of CLEAR Harmony Open-Label Extension Study Data for Bempedoic Acid in the American Journal of Cardiology May 02, 2022 Esperion Announces Publication of Phase 3 Data for Bempedoic Acid in the Journal of Clinical Lipidology Apr 13, 2022 Esperion Announces Two NEXLETOL® (bempedoic acid) Data Presentations at the American College of Cardiology’s 71st Annual Scientific Session & Expo Apr 03, 2022
